Table 3.
Predictive performance of drug clearance in newborns and infants
| Drug | ≥42 weeks PMA |
37 to < 42 weeks PMA |
< 37 weeks PMA |
||||||
|---|---|---|---|---|---|---|---|---|---|
| AFE | AAFE | PER (%) | AFE | AAFE | PER (%) | AFE | AAFE | PER (%) | |
| Drugs with > 90% renal elimination in adults | |||||||||
| Amikacin | 1.3 | 1.5 | 81.8 | 1.2 | 1.4 | 90.9 | 0.8 | 1.3 | 97.3 |
| Gadobutrol | 0.9 | 1.2 | 100.0 | 0.7 | 1.3 | 100.0 | NA | NA | NA |
| Gadoterate | 0.9 | 1.4 | 87.8 | 0.8 | 1.6 | 75.0 | NA | NA | NA |
| Vancomycin | 1.0 | 1.3 | 100.0 | 0.9 | 1.2 | 96.8 | 1.2 | 1.2 | 100.0 |
| Drugs with 60–80% renal elimination in adults | |||||||||
| Gentamicin | 1.2 | 1.2 | 100.0 | 1.2 | 1.2 | 100.0 | 1.0 | 1.2 | 100.0 |
| Netilmicin | 1.1 | 1.1 | 100.0 | 0.6 | 1.7 | 66.7 | 0.7 | 1.5 | 92.4 |
| Meropenem | 1.0 | 1.4 | 92.3 | 1.0 | 1.2 | 100.0 | 1.0 | 1.2 | 98.1 |
| Ampicillin | 1.6 | 1.6 | 80.0 | 2.0 | 2.0 | 54.8 | 2.0 | 2.0 | 51.4 |
AAFE, absolute average fold error; AFE, average fold error; PER, percentage of infants with a fold error between 0.5 and 2, indicating a twofold difference from the observed clearance; NA, not applicable; PMA, postmenstrual age.